Why the study?
Despite treatment improvements, AF remains associated with severe complications, and metabolic syndrome represents a widespread epidemic contributing to its development.
Answers are grounded in this paper and cite their sources.
This review highlights the features of atrial fibrillation development in patients with metabolic syndrome and suggests novel avenues for primary prevention through risk factor modification.
Currently, around 34 million people worldwide suffer from atrial fibrillation (AF), with the number projected to double by 2060. Despite the treatment of AF has been significantly improved during the recent years, AF is still associated with an increased risk of severe complications such as systemic thromboembolism, progression of heart failure, stroke, and myocardial infarction. Due to a high risk of disability and mortality, AF represent a major socioeconomic problem for the healthcare in most countries, also because of related financial costs. Obesity, most often represented by metabolic syndrome, is widely recognized as an epidemic of the XXI century. Here we review the features of AF development in patients with metabolic syndrome, suggesting novel avenues for the primary prevention of AF.
No takes yet. Share an insight, caveat, or question.
Olesin et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: